愛知県がんセンター

What 愛知県がんセンター does

Aichi Cancer Center (愛知県がんセンター) is a prefectural government-operated comprehensive cancer center established in 1964-1965 in Nagoya, Aichi Prefecture, Japan, combining a specialty hospital and a dedicated research institute on a single campus at 1-1 Kakanodori, Chikusa-ku. It serves primarily Aichi Prefecture residents and regional referrals, functioning as the designated core cancer medical coordination base hospital (がん診療連携拠点病院) for the prefecture and coordinating continuity of care with local hospitals and clinics through a dedicated Medical Coordination Office and shared clinical pathways for major cancers.

The hospital runs 30+ clinical departments spanning gastroenterology, respiratory medicine, hematology, multiple surgical oncology specialties, radiology, and pathology, organized around specialized centers including the Genomic Medicine Center, Rare Cancer/Sarcoma Center, Outpatient Chemotherapy Center, and Palliative Care Center. The research institute operates alongside the hospital with infrastructure for genome sequencing, a biobank, a GMP-compliant clean room for physician-led cell and regenerative therapy, SPF and genetic-engineering animal facilities, and radioisotope laboratories; it conducts priority translational projects, clinical trials, cancer registry and statistics work, and consultation support services. Service lines also include public lectures, palliative care training, in-hospital cancer registrar training, and contract/outsourced research management.

The institution is funded through regulated medical service fees under Japan's national health insurance system for consultations, examinations, treatments, surgeries, hospitalizations, and diagnostics, supplemented by prefectural government appropriations and research grants; patient access is referral-based, with new patients required to submit referral documents through the Medical Coordination Office prior to appointment scheduling. Research output is actively disseminated through press releases, peer-reviewed publications, public lectures, and since December 2024 an official YouTube channel and social media accounts at the research institute level. Recent strategic moves have emphasized deepening partnerships, including a comprehensive cooperation agreement with Nagoya University (February 2025), a 60th anniversary joint symposium with MD Anderson Cancer Center (March 2025), and a joint research collaboration with Kitasato University discovering novel anti-mesothelioma compounds from soil-derived fungi (June 2026).

Name

愛知県がんセンター

Legal name

愛知県がんセンター

Website

https://cancer-c.pref.aichi.jp

Company type

Private

Founded year

1965

Operating status

Operating

Headcount range

11–50 employees

Short description

Aichi Cancer Center is a prefectural government-run comprehensive cancer center in Nagoya combining a specialty hospital and research institute to deliver advanced oncology care, genomic medicine, clinical trials, and palliative services to Aichi Prefecture residents and regional referrals.

Ownership category

akta.pro rank

Product category

Specialty Cancer Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111), Diagnostic Imaging Centers (621512)

SIC

Services-Hospitals (8060), Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB)

Keywords

• Cancer treatment services
• Genomic medicine
• Clinical trials
• Palliative care
• Cancer research

Headquarters

HQ city

Nagoya

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Others

Revenue model

1. Medical Service Fees: Revenue from medical consultations, examinations, treatments, surgeries, hospitalizations, and diagnostic services provided to cancer patients. As a designated cancer medical institution, fees are regulated under Japan's national health insurance system.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Aichi Cancer Center (愛知県がんセンター) operates as an integrated comprehensive cancer center combining a hospital and a research institute. The hospital delivers specialty cancer care across 30+ clinical departments and dedicated centers (Genomic Medicine, Rare Cancer/Sarcoma, Outpatient Chemotherapy, Palliative Care), while the research institute conducts genomic, drug-therapy, and translational cancer research. The center also offers cancer consultation support, cancer registry/statistics, regional clinical pathways, and professional training for cancer registrars and palliative care practitioners.

Product overview

愛知県がんセンター operates as a comprehensive cancer center combining a hospital and research institute. The institution offers a unified portfolio of cancer care services organized around specialized centers including the Genomic Medicine Center, Rare Cancer & Sarcoma Center, Outpatient Chemotherapy Center, and Palliative Care Center. The hospital provides clinical services across multiple departments (gastroenterology, respiratory medicine, hematology, surgery divisions for various cancer types, radiology, etc.) while the research institute conducts priority cancer research projects. The center also provides cancer information services, clinical trials, regional clinical path coordination for major cancers, cancer consultation support, and professional training programs for cancer registry practitioners.

Differentiator

Problem solved

Functional benefit

Products and services

• Genomic Medicine Center (ゲノム医療センター) Specialized center that uses cancer genomic information and individual genetic information to provide personalized cancer diagnosis, treatment, and prevention tailored to each patient, based on the latest medical evidence.
• Rare Cancer and Sarcoma Center (希少がん・肉腫センター) Specialized center providing multidisciplinary specialist discussion and comprehensive treatment approaches for rare cancers, sarcomas, and cancers of unknown primary, where each patient's tumor is unique and requires a tailored, multimodal plan.
• Outpatient Chemotherapy Center / Cancer Drug Therapy Department (外来化学療法センター / がん薬物療法部) Outpatient chemotherapy center delivering cancer drug therapy by specialists in cancer chemotherapy and various cancer pathologies, providing optimal anti-cancer drug treatment from a continually advancing therapeutic portfolio.
• Palliative Care Center (緩和ケアセンター) Provides palliative care services that improve quality of life for cancer patients and their families through pain management, symptom relief, and psychological support across the care continuum.
• Clinical Trials (臨床試験) Clinical trials conducted with patient cooperation to generate evidence for the efficacy and safety of new cancer treatment methods, generating evidence that supports next-generation cancer medicine.
• Aichi Prefecture Cancer Registry and Statistics (愛知県のがん登録・統計) Cancer registry and statistics services providing epidemiologic data on cancer incidence and outcomes across Aichi Prefecture for population-level cancer control and countermeasure planning.
• Regional Clinical Pathways (地域連携クリニカルパス) Regional coordination clinical pathways for major cancers (colorectal, gastric, liver, lung, breast, prostate, thyroid) that enable continuity of care between the cancer center and regional hospitals and clinics.
• Cancer Consultation Support Center (がん相談支援センター)

Quantifiable outcome

• Designated as prefectural cancer medical coordination base hospital

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• Kitasato UniversitycoreStrategic or Co-development Partner · 17 June 2026Joint research collaboration discovered novel compounds from soil-derived fungi effective against malignant mesothelioma. The partnership combines Kitasato University's natural product chemistry expertise with Aichi Cancer Center's cancer research capabilities.
• MD Anderson Cancer CenterflagshipStrategic or Co-development Partner · 11 March 2025Joint symposium held to commemorate the 60th anniversary of the Aichi Cancer Center. Collaboration on advanced cancer research and treatment methodologies with the globally renowned cancer center based in Houston, Texas.
• Nagoya UniversitycoreStrategic or Co-development Partner · 17 February 2025Comprehensive agreement for enhanced collaboration signed February 17, 2025. The partnership aims to strengthen cooperation between the cancer center's clinical expertise and the university's academic research capabilities in advancing cancer treatment and research.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Princess Margaret Cancer Centre (University Health Network): Major specialty cancer center affiliated with a research university. Comparable in combining advanced clinical oncology with research programs, genomic medicine, and rare-cancer expertise, but operates at a much larger national/international scale.
• National Cancer Center (Japan): Japan's flagship national cancer hospital and research institute operating under the national government. Directly comparable as a government-run specialty cancer center combining hospital and research functions, with national rather than prefectural scope.
• Gustave Roussy Institute: Leading European specialty cancer center combining hospital and research functions with genomic medicine, rare cancer programs, and clinical trials. Comparable structurally as a public-sector comprehensive cancer center focused on translational research.
• The Christie NHS Foundation Trust: Large U.K. public-sector specialist cancer hospital offering comprehensive oncology services and research. Comparable as a publicly operated specialty cancer center with clinical trials and multidisciplinary care, though serving a different national health system.
• Osaka International Cancer Institute: Prefectural comprehensive cancer center in Osaka combining hospital and research functions. Closest structural peer: same hospital-plus-research-institute model with prefectural government ownership and designated cancer coordination role.

Broad incumbents

• Moffitt Cancer Center: U.S. specialty cancer hospital with integrated research institute model similar to Aichi. Comparable as a dedicated oncology institution combining clinical care with translational research, though operating in a different payment and scale environment.
• Memorial Sloan Kettering Cancer Center: Global leader in specialty cancer care and research. Comparable as a hospital-plus-research-institute oncology institution with multidisciplinary specialty departments and advanced therapy programs, though at vastly greater scale and funding.
• MD Anderson Cancer Center: Globally leading U.S. cancer center and named partner of Aichi Cancer Center. Comparable as a specialty cancer hospital with intensive research focus, though far larger in scale, scope, and funding base.
• Nagoya University Hospital: Academic medical center in the same Aichi/Nagoya region with which Aichi Cancer Center has a comprehensive cooperation agreement. Comparable as a regional tertiary oncology provider, but broader in scope (general hospital) and tied to a top research university.

Emerging players

• German Cancer Research Center (DKFZ): National biomedical research institute focused exclusively on cancer with affiliated translational/clinical programs. Comparable in the research-institute leg of Aichi's hybrid model, though without DKFZ's national-level funding base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ACCRI_Official
• YouTubeyoutube.com/@%E6%84%9B%E7%9F%A5%E7%9C%8C%E3%81%8C%E3%82%93%E3%82%BB%E3%83%B3%E3%82%BF%E3%83%BC%E5%BA%83%E5%A0%B1
• Facebookfacebook.com/ACCResInst
• Instagraminstagram.com/accri_official
• LinkedInlinkedin.com/company/%E6%84%9B%E7%9F%A5%E7%9C%8C%E3%81%8C%E3%82%93%E3%82%BB%E3%83%B3%E3%82%BF%E3%83%BC

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 愛知県がんセンター